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Background: Stratified Medicine (SM) is becoming a practical reality with the targeting
of medicines by using a biomarker or genetic-based diagnostic to identify the eligible
patient sub-population. Like any healthcare intervention, SM interventions have costs
and consequences that must be considered by reimbursement authorities with limited
resources. Methodological standards and guidelines exist for economic evaluations
in clinical pharmacology and are an important component for health technology
assessments (HTAs) in many countries. However, these guidelines have initially been
developed for traditional pharmaceuticals and not for complex interventions with multiple
components. This raises the issue as to whether these guidelines are adequate to SM
interventions or whether new specific guidance and methodology is needed to avoid
inconsistencies and contradictory findings when assessing economic value in SM.
Objective: This article describes specific methodological challenges when conducting
health economic (HE) evaluations for SM interventions and outlines potential
modifications necessary to existing evaluation guidelines /principles that would promote
consistent economic evaluations for SM.
Results/Conclusions: Specific methodological aspects for SM comprise
considerations on the choice of comparator, measuring effectiveness and outcomes,
appropriate modeling structure and the scope of sensitivity analyses. Although current
HE methodology can be applied for SM, greater complexity requires further methodology
development and modifications in the guidelines.
Keywords: stratified medicine, health technology assessments, guidelines, reimbursement mechanisms,
reimbursement, biomarkers
INTRODUCTION
The concept of “Stratified Medicine”(SM) is becoming a practical reality with the targeting of
medicines by using a biomarker or genetic-based diagnostic to identify the eligible patient sub-
population (Payne and Annemans, 2013). The quantity of biomarkers, prognostic, and diagnostic
tests available for patients has increased significantly over the last decade and SM interventions are
increasingly being developed and used in clinical care. In the SM concept, subgroups of responders
are selected or identified based on risk of disease or response to therapy, with the notion to
improve treatment outcomes in these subgroups by increasing efficacy and/or reducing toxicity.
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This stratification of the population by using diagnostic tests or
techniques is intended to reduce the use of ineffective or unsafe
drugs, which should translate into improved health outcomes
for patients and more efficient use of health care resources.
However, there is much debate and uncertainty on which SM
tests provide economic value and how to balance the need for
innovative new technologies with affordability. Decision makers
and stakeholders need information on which tests provide added
value in order to make appropriate decisions about where to
invest efforts in development and adoption (Phillips et al., 2014).
A number of analysts have observed that the promise of SM is
yet to be realized, partly due to the lack of sufficiently robust
clinical and economic evidence based to support the widespread
use in clinical practice (Faulkner et al., 2012; Berger and Olson,
2013; The Academy of Medical Sciences, 2013; Phillips et al.,
2014; Rogowski et al., 2014). Several published systematic reviews
had suggested there are limitations in the quantity and quality of
economic evaluations of examples of targeted therapies, imposed
by weak clinical and economic evidence base (Vegter et al.,
2010; Wong et al., 2010; Hatz et al., 2014). Annemans et al.
as well as Buchanan et al explored methodological challenges
of conducting economic evaluations of targeted interventions,
and outlined new measurement issues for traditional cost-
effectiveness analysis (CEA) when adding a test or sequence
of tests into the clinical car pathway (Annemans et al., 2013;
Buchanan et al., 2013). Furthermore, there is uncertainty in
methods to be used with testing of multiple biomarkers or clinical
applications based on whole exome or genome sequencings.
In addition, challenges arise if the economic evaluation of SM
interventions is understood as an evaluation of the benefits,
harms and cost-effectiveness at the individual patient preference
level; (Basu, 2011; Rogowski et al., 2014) it should rather be
conceived as applying to subpopulations as a whole.
Methodological standards and guidelines exist for economic
evaluations in clinical pharmacology and are an important
component of programs for health technology assessment
(HTAs) in many countries. However, these guidelines have
initially been developed for traditional pharmaceuticals and not
for complex interventions with multiple components. This raises
the issue as to whether these standards and guidelines are
adequate to address more targeted approaches to therapy or
whether new specific guidance and methodology is needed to
avoid inconsistencies and contradictory findings when assessing
economic value in SM.
This article addresses key methodological issues and
challenges when conducting health economic evaluations for
SM interventions and outlines potential modifications necessary
to existing evaluation guidelines and principles that would
promote consistent economic evaluations for decision making
in SM. Utilizing a set of criteria represented by the guidelines
for cost-effectiveness (such as, ISPOR, NICE)1,2 we identified
1Pharmacoeconomic Guidelines Around The World, www.Ispor.org/
PEguidelines/index.asp
2National Institute for Health and Clinical Excellence. The guideline manual—
assessing cost effectiveness, https://www.nice.org.uk/guidelinemanual/7-
assessing-cost-effective
various aspects of the criteria/guidelines which require specific
attention/modification for SM interventions.
SPECIFIC METHODOLOGICAL ASPECTS
IN SM
While the basic framework for economic evaluations of SM
interventions is similar to traditional clinical pharmacology some
specific issues and challenges can be identified and assessed based
on economic evaluation checklists2 (Huseruau et al., 2013; see
Table 1).
PERSPECTIVE AND TARGET AUDIENCE
Health Economic evaluations can be performed from the
perspective of the society and the national third party payer
according to country-specific economic guidelines in health
technology assessments. From a methodological point of view,
the societal perspective should be preferred over the national
third party payer perspective, especially for SM, which requires a
more system wide (holistic) approach to perceive the full health-
and economic- value taking into considerations costs and long-
term benefits having less adverse therapies target toward those
who benefit most. However, in practice most economic analyses
of SM interventions are performed from a third party perspective,
since there is no longitudinal accounting in many healthcare
systems in EU and the US which would enable payers to capture
long-term cost savings from near-term testing. In addition,
pharmaceuticals and diagnostics are considered under separate
appraisal and payment processes in many healthcare systems.
Only NICE (UK) has so far established a Diagnostic Assessment
program (DAP) which carries out cost-effectiveness assessments
of selected diagnostics (Bücheler et al., 2014). Funding silos
may lead to different payer perspectives, e.g., those who pay for
drugs vs. those pay for diagnostic requiring different questions.
Hence, the defined perspective which determines the relevant
cost and benefits relates much to the discussion on the target
audience. For instance, in hospital setting, diagnostic testing is
covered by the fee-based DRG system in several EU countries
(e.g., Germany, France) or on budget-based systems (e.g., UK,
Spain) where a global budget is allocated to local budget holders
for payment processes. Further specification of what defines a
third party payer, a clear understanding of target audience and
broadening to societal perspectives will increase relevance of
policy decision making and is useful to identify their evidence
needs and incentives to adopt a new technology when proven
valuable.
TARGET POPULATION AND
COMPARATORS
SM interventions may accelerate the evolution and development
of clinical treatment pathways which makes the specification of
target populations groups a challenge. Technological advances
in genetic sequencing and identification of biomarkers have
made it feasible to test multiple biomarkers to inform treatment
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TABLE 1 | Summary of methodological issues in economic evaluations of SM interventions.
Statements Guidelines Issues /challenges Possible solutions/new guidance
Perspectives and Target
Audience
Societal or third party Societal perspective is preferred (ideally), although
third-party is most used. Funding silos may lead to
different payer perspectives, i.e., those paying for
drugs vs. those paying for diagnostics.
Clear understanding of target audience and
further specification of what defines a
third-party-payer will increase relevance for
decision-making.
Target Population Clear description of target
population and subgroups
analyzed.
Testing reveals heterogeneity and creates multiple
subgroups & treatment pathways which may
challenge specification of target population groups.
Identifying the exact place of a test within care
pathway is critical.
Specification of target populations groups
according testing rules will guide the selection
of relevant comparator and may reduce
variability of evaluation findings.
Comparators Standard care being most widely
used.
Multiple potential test designs may exist and makes
defining testing interventions a challenge. The
sequence of testing and the inclusion of a “no test”
comparator is often variable and can lead to
different coverage recommendations.
An additional comparison should be considered
by splitting the SM treatment. A comparison of
the “test first with the new compound/drug” vs.
“treat all with new compound/drug” vs.
“standard care” is crucial for payers.
Measuring Effectiveness Systematic review; incorporate
real-world factors that modify
effectiveness which also may
include indirect comparisons.
Estimates of effectiveness relies on various data
sources and is more sensitive to adherence and
compliance effects.
Strict recommendations that compliance and
adherence must be accounted for in sensitivity
analysis.
Valuing outcomes Use appropriate
preference-based measures to
value differences between the
intervention and alternatives
(e.g., OALY).
Standard measures (e.g., QALY) have limited
applicability and are focused on average population
rather than individual/sub-population outcomes. Yet
alternative metrics (e.g., personal utility) are
underdeveloped and alternative approaches (e.g.,
cost-benefit analysis) are underused.
Recommendation to incorporate local utilization
patterns to improve behavioral assumptions.
Further research is needed for quantifying
non-health outcomes in evaluations.
Costs and resource use Measure and value resources
that are relevant to study
perspective.
Establishing and projecting the additional costs due
to testing is challenging.
National price lists of diagnostic test (unit) costs
would help avoid reporting variations in costs.
Modeling Inclusion of sensitivity/specificity and especially
false- negative and false- positive considerations will
increase structural complexity to establish the
relationship between test results and treatment
changes and outcomes.
An iterative approach to evaluation is
recommended (via early modeling) to identify
the need for further evidence generation in
alignment with HTA requirements.
Uncertainty Sensitivity analyses Extra sensitivity analyses are required for
sensitivity/specificity and cost of the test.
Scenario analyses may be more important in
SM; especially when considering test
characteristics and potential evidence gaps.
choices, or use algorithms to target screening interval strategies.
Also next generation sequencing and whole genome or exome
sequencing may allow identifying mutations in multiple genes
for multiple conditions in parallel. As a consequence, the number
of pathways to include into a model-based economic evaluation
may grow exponentially with the number of biomarkers used for
stratification (Rogowski et al., 2014). A recent evaluation of a
gene recurrence score assay enumerated 1000 potential clinical
strategies from 24 clinical testing pathways and 12 unique risk
categories based on two tests with two chemotherapeutic regimes
(Paulden et al., 2011).In this context it is important to consider
that targeted subgroup-specific treatment strategies are clinically
plausible and implementable. Identifying the exact place of a SM
test within care pathways is crucial and may change the cost-
effectiveness outcomes of the intervention (e.g., different results
of HER2 testing of trastuzumab in breast cancer patients with
adjuvant vs. metastatic settings). This will guide the selection of
a relevant comparator - which is usually current standard care
in economic evaluations conducted for HTA’s -, and determines
the appropriate clinical testing strategies to be modeled. Unlike
traditional interventions, SM interventions should have at least
two comparators: comparisons of the “test first with the new
compound/drug” vs. “treat all with new compound/drug” and vs.
“standard of care” are recommended although various published
cost-effectiveness studies to date have used only the “treat all”
strategy as a comparator and ignored the “standard of care”
(treat-none with new drug) option. From payers’ perspectives,
comparisons of the SM approach with “standard care” is often
crucial (Merlin et al., 2013). For example, a cost-effectiveness
analysis of KRAS testing with cetuximab in colorectal cancer
performed by Shiroiwas et al in Japan considered three treatment
strategies and outlined that the test-first strategy with cetuximab
was dominant vs treat-all-with cetuximab but perhaps not cost-
effective vs. the treat-none-with cetuximab strategy (Shiroiwa
et al., 2010).
MEASURING EFFECTIVENESS AND
OUTCOMES
There is general acknowledgement that the quality of
effectiveness data for SM interventions is often weak and
Frontiers in Pharmacology | www.frontiersin.org 3 May 2016 | Volume 7 | Article 113
Fugel et al. Economic Evaluation of Stratified Medicine
challenging to incorporate into standard health economic
analyses (Goddard et al., 2012). Effectiveness of SM intervention
is a function of both the efficacy of drug and the accuracy of
the test and includes considerations on false-positive and false-
negative outcomes of testing. One reason why there are relatively
few assessments of economic value is that many diagnostic tests
do not have widely accepted evidence of clinical utility, i.e.,
linking test use to patient outcomes. The issues surrounding
the definition and measurement of clinical utility are major
areas of debate for all kinds of diagnostic testing technologies.
Currently, regulators do not require proof of clinical efficacy for
a test or even sensitivity/specificity specification which could be
used to estimate model effectiveness. Furthermore, data on the
effectiveness of laboratory-developed tests is often even more
limited due to the ad hoc nature of their development (Faulkner
et al., 2012).
There are differences in the evidence generation for the SM-
development scenarios. For a test developed in association with
a drug (co-development), the economic analysis might be based
on randomized controlled trials (RCTs), where the diagnostic
test was included in the clinical studies of the drug’s efficacy;
i.e., sensitivity/specificity data of the test as well as efficacy data
of the drug/diagnostic combination are included in the overall
outcomes of the trial, which can produce direct evidence of the
clinical utility of the test. For a stand-alone test, this is much
harder to achieve as RCT’s are often not feasible because of
ethical reasons, shift to multi-therapeutic regimes, and lack of
resources or small patient populations. Real-life data generation
is increasingly needed in this case perhaps via prospective cohort
studies, observational studies or chart review, as payers might
seek additional post-market evidence for clinical utility. It is
becoming increasingly apparent that new methods will have to
evolve to ensure efficient evidence generation reflecting realistic
expectations around evidence standards (thresholds) aligned
between stakeholders given the pace of genomic discovery and
the associated costs. This implies that health economists and
decision makers must be prepared to accept data that have come
from different settings (case-control and observational) outside
RCT’s. Potential alternative solutions may involve the use of
novel trial designs, such as adaptive clinical trials.
Furthermore it is to consider, that the overall effectiveness
of the SM intervention doesn’t only rely on the development
of new treatment modalities, but also on providers and
patients behavior when using diagnostic-based therapies.
How patients are managed in practice is important and will
influence the adoption of new technologies (e.g., examples
warfarin PGx testing and TMPT testing for patient taking
6-mercaptopurine or allopurinol). SM underscores the
need for additional information on patients and physicians
response to diagnosis and will require post-approval data
collection. Accounting for compliance and adherence (e.g.,
by use of local utilization pattern to improve behavioral
assumptions) will reduce variability of findings and should
be incorporated into sensitivity analyses. The recently drafted
guidelines for preparing assessment reports for the Medical
Services Advisory Committee- Service Type: Investigative
(version 1.3) in Australia specifically request a supplementary
analysis of the non-health related impacts of diagnostic
testing 3.
The impact of an intervention on health status (e.g., cost
per QALY’s or life year saved) is the preferred outcome
measure for several EU governmental advisory bodies (e.g.,
NICE, SMC, TLV, or CRM) as recommended in the health
economic guidelines. However, for third party payers such
standardmeasures may have limited applicability in assessing SM
interventions rather requesting cost-offsets and budget impact
information to address affordability issues in various health
care systems. Methodological issues regarding the valuation of
health outcomes for SM, particular the quality-adjustment of
utility component in QALYs, are similar to those faced by
other health care intervention. There is an ongoing discussion
in academia how standard value assessment metrics can be
expanded by personal utility data, as current metrics is focussed
on average population based preferences rather than individual
patient preference valuation. Capturing information on personal
utility may be important, because additional benefits may
arise from a patient’s increased certainty about the likelihood
of successful treatment—the “value of knowing” (although
ultimately always to be aggregated to population levels). This
might affect adherence and thereby patient outcomes. Yet,
alternative metrics (e.g., personal utility) are underdeveloped
or alternative approaches underused (e.g., state of choice,
willingness to pay) in policy decision making (Buchanan et al.,
2013). Further, research in this area is required to provide
guidance for quantifying and incorporating non-health outcomes
in economic evaluations.
ESTIMATE RESOURCE USE AND COST
The costing methodology is straightforward and there may not
be methodological differences with the costing methodology
in health economic evaluations for traditional pharmaceuticals.
Cost calculations in economic evaluation require total average
costs (including capital and allocated overhead costs) derived
from resources consumed and unit cost measures based on
economic (opportunity costs; Conti et al., 2010) Yet, establishing
and projecting the additional costs due to testing may provide
challenges for analysts. A broad range of direct testing costs may
include additional clinic visits, sample collection and testing, the
cost of subsequent treatment and genetic counseling as well as re-
testing considerations. However, the complete estimation of costs
relates to the type of cost items and primarily not amethods issue,
beyond the perspective chosen.
Often, there are challenges to identify the unit cost of
tests which may depend on number of tests performed or be
part of platform diagnostics with multiple applications. Unlike
pharmaceutical, there is no national list of available genomic
or other tests, as often each laboratory is free to set their own
price (or charge) to clinicians requesting the test and negotiations
3www.health.gov.au/internet/hta/publishing.nsf - technical guidelines for
preparing assessments reports for the Medical Services Advisory Committee
- Service Type: Investigative (version 1.3). Draft for public consultation 2015;
www.pbs.gov.au/pbac-guidelines/product type 4- hybrid technologies and
co-dependent technologies, Version 5.0, March 2016
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between suppliers and users often occur at local levels. Large
variation in the unit cost of these tests can affect the findings of
an economic evaluation and increase uncertainty in the estimated
relative cost-effectiveness of a test. Sensitivity analysis should
address robust cost estimates relevant to diagnostic testing, yet
national price lists of diagnostic test costs would help avoid
the currently reported variation in costs (NHS-UK Genetic
Testing Network, 2011). One costing question is related to the
perspective. If we assume that a test is performed in an inpatient
setting, then from a payer perspective, only the diagnosed related
group (DRG), including all inpatient resource utilization, needs
to be applied and the hospital must take care of being able
to finance the test within the DRG. However, from a societal
perspective, the cost of the test should be added to the DRG
assuming that the current DRG reflects an opportunity cost to
the hospitalization. Therefore, micro-costing approach would be
most appropriate in order to capture the real/true costs.
MODELING AND DEALING WITH
UNCERTAINTY
The existing modeling techniques are appropriate and can
be applied for cost-effectiveness models in SM, given that
special issues are taken into consideration. The inclusion of
sensitivity/specificity and especially false negatives and false
positives, requires additional structural complexity in order to
make the link between the test and the medication and the
subsequent clinical and economic outcomes. Another issue is
dealing with gaps in the evidence base, especially for stand-alone
tests. Information on treatment patterns, its costs and outcomes,
are often lacking, especially for false positive and false negative
patients. There is a need to identify best practices for economic
modeling including approaches which address these evidence
gaps in a manner that is both acceptable to payers and feasible
for test manufactures. Thus, extrapolation methods are required
in order to extrapolate the short-term sensitivity/specificity data
to long-term economic outcomes, as shown in a recent paper
by Fugel and Nuijten (2014) Given that health economists will
increasingly be faced with poor quality effectiveness and cost
data early modeling approaches will become more common in
early development stages to better understand the HE value of
new technologies. An iterative approach could then be employed
that systematically and explicitly considers the need for further
evidence to reduce decision uncertainty, and is consistent with an
approach to HTAs known as constructive technology assessment
(Sculpher et al., 1997; Shabaruddin et al., 2015).
Sensitivity analyses aim at providing information on the
degree of uncertainty in economic evaluations and it is currently
the most widely applied method of dealing with uncertainty
in economic evaluations (Critchfield et al., 1986). Because of
the more complex structure, lack of data, and extrapolation,
the uncertainty level in the SM model is higher than in a
comparable model for traditional pharmaceuticals. In addition,
the efficacy of the stand-alone test is often based on a small
sample size leading to extra uncertainty, thus, extra sensitivity
analyses are required for sensitivity/specificity and cost of the test.
In SM, there are more gaps in information and the number of
possible assumptions increases with the number of parameters
added which may cause interpretation problems. A practical
way to overcome this problem is the use of scenarios, in which
several factors are set to reflect a specific situation, such as
the best-case and worst-case scenarios (Vegter et al., 2008).
Hence, for the SM approach, scenario analyses may be more
important than sensitivity analyses, especially when considering
test characteristics and potential evidence gaps, because there are
rather issues on the quality of the data than the distribution of
the variable. The structural uncertainty of the assumptions due
to gaps in data is larger than the uncertainty due to statistical
distribution. Specific scenario analyses in SM, which are not
relevant in traditional pharmaceuticals, may be required for a
range of estimates in turn, but it may also be possible to perform
a “multi-scenario” analysis, where the effect of simultaneous
changes in different assumptions is examined on the outcomes
of the study.
A probabilistic sensitivity analysis (PSA) permits the analyst to
assign a range and distribution to input variables (Doubilet et al.,
1985). The results of a PSA are presented in a cost-effectiveness
acceptability curve, which displays the probability that a new
treatment is the most cost-effective treatment considered in the
analysis at a range of different threshold ICER values representing
what society might be willing to pay to gain one e.g., QALY.
However, the results of a PSA for SM may need to be considered
with more prudence than with traditional pharmaceuticals. Gaps
in information and subsequent assumptions cannot be captured
by a statistical distribution and therefore this type of uncertainty
cannot be included fully in a PSA.
CONCLUSION AND FUTURE RESEARCH
In general, we can conclude that current health economics
methodology can be applied for SM, although various aspects of
the guidelines require specific attention for stratified medicine
approaches. These aspects comprise considerations on the
choice of comparator, measuring effectiveness and outcomes,
appropriate modeling structure and the scope of sensitivity
analyses. Many of these aspects refer to a lack of evidence
on testing heterogeneity and the quality of effectiveness data.
Notably, the level of economic evidence for SM interventions
may differ from what is generally experienced with traditional
pharmaceuticals, thus stressing the need to identify best practice
for economic modeling including approaches which address
evidence gaps in a manner that is both acceptable for payers
and feasible for test manufactures. This may involve the use
of novel trial designs, such as adaptive clinical trials, evidence
from observational studies, and the use of coverage-with-
evidence development and real-world evidence collection for
both drugs and diagnostics. However, the evaluations of both
test-treatment interventions (companion diagnostic) and stand-
alone diagnostics is occurring in a complex legal, regulatory and
reimbursement environment which does not currently fit with
SM approaches. New incentive structures are needed to increase
the efficiency of evidence generation. Previous suggestions for
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economic incentives for evidence generation include value-based
price flexibility, intellectual property protection from evidence
generated and public investment to complement the effort of
payers and manufactures (Towse and Garrison, 2013).
SM underscores the need for additional information on
patients and physicians response to diagnosis which is not
readily available from clinical trials or administrative data sets.
Accounting for compliance and adherence (e.g., by the use
of local utilization pattern to improve behavioral assumptions)
will provide insight into variability of findings and should be
incorporated into sensitivity analyses. Health economist may
need to take new accountabilities when using observational
research methods to perform additional value from utilization
data to payers.
Incorporating complex genetic or genomic data into cost-
effectiveness analyses is a challenge that will grow as next
generation sequencing technologies enter clinical practice.
While there is no need to develop completely new tools,
there are requirements for some refinement by including
sensitivity and specificity consideration of the test as well as
to address consequences of false-negative and false- positive
test results on the value proposition. This may require further
methodology development to address the increased complexity
and the need for additional analyses associated with the testing
component. Further research should also consider examining
other approaches to measuring values for SM interventions.
The specific aspects outlined in this article suggest there may
be opportunities to improve current guidelines for economic
evaluation of SM interventions.
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